Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype

Abstract excerpt

BACKGROUND: Mepolizumab is approved for patients with severe asthma with an eosinophilic phenotype aged 12 or more (United States) or 6 or more (European Union) years, but its long-term use in children aged 6 to 11 years has not yet been assessed. OBJECTIVE: We sought to assess the long-term safety, efficacy, and pharmacodynamics of mepolizumab in children aged 6 to 11 years with severe asthma with an...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Asthma and respiratory diseases
• Share to Chronic Obstructive Pulmonary Disease (COPD) Research
• Share to Delphi Technique in Research